This is an interactive session between investors and innovators using content designed with active participation from the National Institute on Drug Abuse (NIDA). It will include discussion, a question and answer period, and real examples to illustrate impact.

Together with NIDA, the Milken Institute is accelerating investors' response to evidence-based health technology by highlighting cutting-edge digital-health innovations and investment opportunities in response to the opioid crisis. These advancements address a range of needs, from prevention to treatment—including diagnostics, diversion, mental health, and recovery.

As a continuation of work done earlier this year, this session will feature updates and shared learning from both early and late-stage successes. CEOs of health technology companies will share best practices, along with their experiences navigating barriers and maximizing investment opportunities—including in NIDA's small business programs.

This invite-only session will be moderated by NIDA Director Dr. Nora Volkow. NIDA is part of the National Institutes of Health (NIH).